TiUltra Implant Study

November 11, 2026 updated by: Hanae Saito, University of Maryland, Baltimore

Comparison of Early Healing Dynamics Between NobelActive S TiUltra and NobelReplace CC Ti Unite Implants Using Resonance Frequency Analysis: A Prospective Clinical Study

This prospective clinical study will compare early healing and implant stability between two Nobel Biocare dental implant systems, NobelActive S TiUltra and NobelReplace CC TiUnite. Approximately 30 implants will be randomly assigned to one of the two implant groups and followed for 12 weeks after placement. Implant stability will be assessed using resonance frequency analysis at implant placement and at approximately 2, 4, 6, 8, and 12 weeks. Clinical healing, radiographic findings, and other treatment-related outcomes will also be evaluated during the follow-up period.

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Maryland
      • Baltimore, Maryland, United States, 21231
        • University of Maryland School of Dentistry

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age ≥18 years
  • Male or Female
  • Partially edentulous patients
  • Healed ridges (≥3 months post-extraction with no history of socket preservation or ridge augmentation)
  • Adequate bone volume (no need for major grafting)
  • Sites requiring a single unit implant
  • Provision of informed consent

Exclusion Criteria:

  • Systemic or local disease or condition that would compromise bone metabolism, post-operative healing and/or osseointegration e.g. uncontrolled diabetes with self-reported most recent HbA1C > 8.0 within last six months
  • Systemic corticosteroids or any other medication that would influence bone metabolism, post-operative healing, and/or osseointegration
  • History of osseous degenerative diseases
  • Heavy smoking (>10 cigarettes/day)
  • Bisphosphonate/antiresorptive therapy
  • uncontrolled periodontal disease
  • Irradiated bone
  • Previous history of failed implants
  • Recently grafted/augmented site (< 1 year)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: TiUnite

NobelReplace CC TiUnite dental implant placed according to the manufacturer's recommended surgical protocol.

Experimental: TiUltra

NobelActive S TiUltra dental implant placed according to the manufacturer's recommended surgical protocol.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean Implant Stability Quotient (ISQ) Measured by Resonance Frequency Analysis (RFA)
Time Frame: Day 0 (implant placement) and Weeks 2, 4, 6, 8, and 12

Implant stability will be assessed using an Osstell device/SmartPeg transducer expressed as Implant Stability Quotient (ISQ) values on a scale of 0 to 100. Longitudinal changes in ISQ will be compared between the TiUnite and S-TiUltra implant groups over the 12-week healing period to evaluate differences in implant stability trajectories.

Day 0 (implant placement) and Weeks 2, 4, 6, 8, and 12

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean Implant Insertion Torque (Ncm)
Time Frame: Day 0 (during implant placement)

Insertion torque will be recorded during implant placement and expressed in Newton-centimeters (Ncm).

Day 0 (during implant placement)
Change From Baseline in Radiographic Marginal Bone Level (mm)
Time Frame: Day 0 (baseline) and Weeks 6 and 12

Marginal bone levels in millimeters (mm) will be assessed using standardized periapical radiographs obtained at implant placement (baseline) and at 6 and 12 weeks after surgery.

Day 0 (baseline) and Weeks 6 and 12
Number of Participants With Implant Failure
Time Frame: From Day 0 (implant placement) through Week 12

Implant-related complications, including implant failure and marginal bone loss, will be assessed during the 12-week follow-up period.

From Day 0 (implant placement) through Week 12

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

February 1, 2027

Primary Completion (Estimated)

August 31, 2028

Study Completion (Estimated)

June 30, 2029

Study Registration Dates

First Submitted

October 15, 2026

First Submitted That Met QC Criteria

October 28, 2026

First Posted (Actual)

November 2, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 11, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe